Basic Information
Pergoveris
Regulatory Information
EMEA/H/C/000714
June 25, 2007
16
October 11, 2024
Company Information
the netherlands
Gustav Mahlerplein 102 Ito Toren 1082 MA Amsterdam
Merck Europe BV
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Pergoveris is indicated for the stimulation of follicular development in women with severe luteinising-hormone (LH) and follicle-stimulating-hormone deficiency. In clinical trials, these patients were defined by an endogenous serum LH level < 1.2 IU/l.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Pergoveris. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Pergoveris. For practical information about using Pergoveris, patients should read the package leaflet or contact their doctor or pharmacist.